Live Breaking News & Updates on Advent France Biotechnology|Page 3
Stay updated with breaking news from Advent france biotechnology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Study investigates safety, efficacy of Luxturna in real-world clinical practice healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
Sidonie Fabre Joins Advent France Biotechnology as CFO cioreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cioreview.com Daily Mail and Mail on Sunday newspapers.
SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics GAMUT rod-cone dystrophies such as retinitis pigmentosa rod-cone dystrophies today - Paris, 202 1 - SparingVision (the Company ), a genomic medicines company developing vision saving treatments for ocular diseases, today announces it has entered into a definitive agreement to acquire GAMUT Therapeutics ( GAMUT ), a biotechnology company pioneering a unique gene-independent approach to treat the later stages of rod-cone dystrophies such as retinitis pigmentosa ( RP ). The acquisition, subject to legal formalities and approval by shareholders of both companies, will be paid mostly in new SparingVision shares and is expected to close in Q2 2021. Further financial terms of the transaction are not disclosed. ....
Search jobs 17-Mar-2021 Advent France Biotechnology appoints Alejo Chorny, PhD, as operating partner and head of new Spanish operations Paris, France, and Barcelona, Spain, March 17, 2021 – Advent France Biotechnology (AFB), an AMF-regulated investment company dedicated to life sciences, today announces the appointment of Alejo Chorny, PhD, as operating partner for Spain. His strong scientific background and experience in tech transfer, business development and project evaluation are the perfect blend to develop AFB’s activities in the region. Chorny’s main business objective will be securing a strong, reliable foothold within Spanish early-stage therapeutic projects and exploring the wealth of opportunities for potential investments. ....
AgomAb Therapeutics Raises $74 Million Series B to Advance Regenerative Pathway Modulators Company expands leadership team with CMO Philippe Wiesel, CBO Paul van der Horst and CFO Tolga Hassan AgomAb Therapeutics N.V. announced today the closing of a $74 million Series B financing round led by Redmile Group, with participation from Cormorant Asset Management. All previous investors also participated in the round, including Advent France Biotechnology, Andera Partners, Boehringer Ingelheim Venture Fund, Omnes Capital, Pontifax, and V-Bio Ventures. The proceeds of the Series B will be used to fund clinical proof of concept of the lead program AGMB-101, an HGF-mimetic agonistic antibody, which is currently progressing through IND-enabling studies. The capital will also support further growth of the company s pipeline of drug candidates designed to modulate regenerative pathways to induce functional organ recovery in acute and chronic diseases. In conjunction with ....